Chen M - Search Results

1

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.

Jiang Y, Chen M, Nie H, Yuan Y. Jiang Y, et al. Among authors: chen m. Hum Vaccin Immunother. 2019;15(5):1111-1122. doi: 10.1080/21645515.2019.1571892. Epub 2019 Mar 19. Hum Vaccin Immunother. 2019. PMID: 30888929 Free PMC article. Review.

2

PRMT5 disruption drives antitumor immunity in cervical cancer by reprogramming T cell-mediated response and regulating PD-L1 expression.

Jiang Y, Yuan Y, Chen M, Li S, Bai J, Zhang Y, Sun Y, Wang G, Xu H, Wang Z, Zheng Y, Nie H. Jiang Y, et al. Among authors: chen m. Theranostics. 2021 Aug 28;11(18):9162-9176. doi: 10.7150/thno.59605. eCollection 2021. Theranostics. 2021. PMID: 34522232 Free PMC article.

3

Cancer cell membrane cloaking nanoparticles for targeted co-delivery of doxorubicin and PD-L1 siRNA.

Chen M, Chen M, He J. Chen M, et al. Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):1635-1641. doi: 10.1080/21691401.2019.1608219. Artif Cells Nanomed Biotechnol. 2019. PMID: 31027450 Free article.

4

Targeting the tumour immune microenvironment for cancer therapy in human gastrointestinal malignancies.

Zhang Y, Xu J, Zhang N, Chen M, Wang H, Zhu D. Zhang Y, et al. Among authors: chen m. Cancer Lett. 2019 Aug 28;458:123-135. doi: 10.1016/j.canlet.2019.05.017. Epub 2019 May 21. Cancer Lett. 2019. PMID: 31121212 Review.

5

Circular RNA in cancer development and immune regulation.

Li W, Liu JQ, Chen M, Xu J, Zhu D. Li W, et al. Among authors: chen m. J Cell Mol Med. 2022 Mar;26(6):1785-1798. doi: 10.1111/jcmm.16102. Epub 2020 Dec 5. J Cell Mol Med. 2022. PMID: 33277969 Free PMC article. Review.

6

Wnt signaling pathway in cancer immunotherapy.

Zhou Y, Xu J, Luo H, Meng X, Chen M, Zhu D. Zhou Y, et al. Among authors: chen m. Cancer Lett. 2022 Jan 28;525:84-96. doi: 10.1016/j.canlet.2021.10.034. Epub 2021 Nov 3. Cancer Lett. 2022. PMID: 34740608 Review.

7

Clinical cancer immunotherapy: Current progress and prospects.

Liu C, Yang M, Zhang D, Chen M, Zhu D. Liu C, et al. Among authors: chen m. Front Immunol. 2022 Oct 11;13:961805. doi: 10.3389/fimmu.2022.961805. eCollection 2022. Front Immunol. 2022. PMID: 36304470 Free PMC article. Review.

8

PPARG Activation of Fatty Acid Metabolism Drives Resistance to Anti-HER2 Therapies in HER2-Positive Breast Cancer.

Xiong M, Liu D, Wang X, Ren H, Chi W, Xiu B, Zhang Q, Zhang J, Zhang L, Wang Z, Chen M, Xue J, Chi Y, Wu J. Xiong M, et al. Among authors: chen m. Int J Biol Sci. 2025 Mar 10;21(6):2396-2414. doi: 10.7150/ijbs.99275. eCollection 2025. Int J Biol Sci. 2025. PMID: 40303293 Free PMC article.

9

CRISPR-Cas9 genome editing for cancer immunotherapy: opportunities and challenges.

Chen M, Xu J, Zhou Y, Zhang S, Zhu D. Chen M, et al. Brief Funct Genomics. 2020 May 20;19(3):183-190. doi: 10.1093/bfgp/elz027. Brief Funct Genomics. 2020. PMID: 31788683

10

Comprehensive pan-cancer analysis reveals NUSAP1 is a novel predictive biomarker for prognosis and immunotherapy response.

Zheng H, Wang M, Zhang S, Hu D, Yang Q, Chen M, Zhang X, Zhang Y, Dai J, Liou YC. Zheng H, et al. Among authors: chen m. Int J Biol Sci. 2023 Sep 4;19(14):4689-4708. doi: 10.7150/ijbs.80017. eCollection 2023. Int J Biol Sci. 2023. PMID: 37781040 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

55,666 results

Search Page

Filters